Showing 5931-5940 of 9846 results for "".
- Science of Skincare Summit Coming in Novemberhttps://practicaldermatology.com/news/science-of-skincare-summit-coming-in-november/2460924/Dermatologists Patti Farris, MD and Ted Lain, MD will kick off the Science of Skincare Summit November 6 at JW Marriott Essex House in New York City. The one-day event is dedicted to education on skincare for medical and aesthetic professionals in all specialties, with content delivered
- Cytrellis Secures New Round of Fundinghttps://practicaldermatology.com/news/cytrellis-secures-new-round-of-funding/2460920/Cytrellis has closed a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors, ARCH Venture Partners and PFM Health Sciences. Proceeds will be
- DermWire Special Report: JAK Inhibitors in Dermatologyhttps://practicaldermatology.com/news/dermwire-special-report-jak-inhibitors-in-dermatology/2460916/By Denise Mann, Editor at Large Lots of hope is pinned on Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis (AD), alopecia areata, vitiligo, plus other skin diseases, and the pipeline is full. Will the recent FDA decision to expand the boxed w
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti
- Study Highlights Severe AD, Depression Linkhttps://practicaldermatology.com/news/study-highlights-severe-ad-depression-link/2460907/Severe atopic dermatitis (AD) travels with depression, a new study shows. In a study of 11, 181 kids, severe AD was associated with an approximately 2-fold increase in the likelihood of symptoms of depression and internalizing symptoms across childhood, compared to eczema-free kids.&nbs
- Sciton Rolls Out BBLINK Goggles for Improved Eye Protectionhttps://practicaldermatology.com/news/sciton-rolls-out-bblink-goggles-for-improved-eye-protection/2460903/Sciton Inc. is launching BBLINK Goggles. These smart glasses physically blink for the user to block out strain inducing light flashes, leading to improved treatment visibility and a more pleasant experience for the practitioner. BBLINK Goggles feature proprietary technol
- New Melanoma Staging System May Better Predict Prognosishttps://practicaldermatology.com/news/new-melanoma-staging-system-may-better-predict-prognosis/2460901/A new system for classifying melanoma when the disease has spread to the lymph nodes may offer a better tool for predicting patients' outcomes and determining their treatment needs, according to research in
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%).
- Study: Dupixent Improves AD Symptoms in Kids As Young As Six Monthshttps://practicaldermatology.com/news/study-dupixent-improves-ad-symptoms-in-kids-as-young-as-six-months/2460898/Dupixent (dupilumab) significantly reduces signs and symptoms of moderate-to-severe atopic dermatitis in children as young as six months, a new study shows. The trial met its primary and all secondary endpoints, showing that Dupixent added to standard-of-care topical corticosteroids (TC